

Developing a novel and **durable** treatment for retinal diseases

CORPORATE PRESENTATION FEBRUARY 2022

# AsclepiX Overview

CASCLEPIX	Clinical-stage biotech leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases						
Ş	<ul> <li>AXT107: first-in-class integrin regulator</li> <li>Novel multi-targeted MOA inhibits VEGF and activates TIE2</li> <li>Following IVT, forms into a gel and expected to have longer lasting durability</li> </ul>						
	Strong global IP portfolio (through 2039)						
	Completed \$35M Series A in June 2020						
	PERCEPTIVE ADVISORS ENCOROUND OF HIBISCUS BIOVENTURES ADVISORS						

## Strong Leadership and Advisory Team

### Management

Prominent biopharma executives with extensive drug development and commercial product experience in ocular diseases



 Robert J. Dempsey, MBA

 Chief Executive Officer and President

 TearClear
 NOVARTIS
 Takeda
 Chire



Amir Shojaei, Pharm.D., Ph.D. Chief Scientific Officer



Niranjan B. Pandey, Ph.D. Vice President, Research & Innovation

### Founders & Scientific Advisory Board

Renowned researchers developed groundbreaking computational biology portfolio in-licensed by AsclepiX

Aleksander S. Popel, Ph.D. Founder, Chief Scientific Advisor, Johns Hopkins School of Medicine

**Peter A Campochiaro, M.D.** Founding Scientific Advisor, Professor, Johns Hopkins School of Medicine

**Jordan Green, Ph.D.** Founder, Chief Technology Advisor, Professor, Johns Hopkins School of Medicine

### **Board of Directors**

**Steven Altschuler, M.D.** *Chairman; Managing Director, Ziff Capital* 

Robert J. Dempsey, MBA CEO and President

Josh Barer Managing Director, Hibiscus Bioventures and Barer & Son Capital


Ben Askew, Ph.D. Partner, Xontogeny **Chris Garabedian** *CEO, Xontogeny PXV Fund, Perceptive Advisors* 

Jordan Green, Ph.D. Founder & CTA, AsclepiX

Sapna Srivastava, Ph.D. Previously CSO and CFO, Abide Therapeutics

# nAMD (Neovascular AMD) and DME

**Neovascularization**, the formation of abnormal blood vessels under the retina, and **vascular leakage** are the hallmarks of both diseases, ultimately leading to vision loss



# Growing nAMD Market Opportunity (~\$11B)<sup>1</sup>


### **Age-Related Macular Degeneration (AMD)**



### AMD (wet and dry) affects ~11M individuals in the U.S.<sup>2</sup>



While nAMD (1.1M) is less common than dry AMD, nAMD accounts for the vast majority (90%) of AMD-related vision loss in the U.S.<sup>3,4</sup>



<sup>1.</sup> Pennington K, DeAngleis M. Epidemiology of age-related macular degeneration (AMD):

associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016; 3: 34.

<sup>2.</sup> Mulligan K, et al. JAMA Opthalmol. 2020; 138(1):40-47.

<sup>3.</sup> Baumal CR. Am J Manag Care. 2020; 26(5 suppl):S103-S111

<sup>4.</sup> Rosenfeld et al. New England Journal Medicine 2006; 355: 1419-1431

<sup>5.</sup> Brown et al. New England Journal Medicine 2006; 355:1431-1444

<sup>6.</sup> Gonzalez et al. (2016) Am J Opthalmol, 172:72-79

### nAMD High Treatment Burden with Consequences for Efficacy

Approved anti-VEGF monotherapies require patients to undergo IVTs every 1-2 months (5-12x a year), leading to treatment avoidance Treatment visits require an accompanying caregiver; patients must rely on others in order to maintain treatment regimen

#### **ASRS Global Preference and Trends (PAT) Survey**

# **Greatest unmet needs in nAMD treatment**<sup>\*</sup>



### Lead program: nAMD

Product Candidates	Program Area	Preclinical	Phase 1/2a	Phase 2/3			
AXT107	Ophthalmology						
	Neovascular Age Related Macular Degeneration (nAMD)						
	Diabetic Macular Edema (DME)						
	Retinal Vein Occlusion						
AXT108	Ocular Surface Disease						
AX 1 108	Ocular Surface Disease						

AXT201	Oncology
	Triple-Negative Breast Cancer
	Solid Tumor




# Lead Candidate: AXT107



### AXT107: NCE With Unique Multi-Targeted MOA

### First-in-class integrin regulator and the first product candidate designed to impact 3 key pathways



## AXT107: Competitive Advantage

AXT107	i 🧹	First-in-class integrin regulator	<ul> <li>✓ Multi mode action</li> </ul>	es of	<ul> <li>Potent inhibition of VEGF family</li> </ul>	long	ificantly er durabil pared to S	
	Inhibits VEGF-A	Inhibits VEGF-C	ANG2 Inhibitor	Activates TIE2 pathway (ANG1 & ANG2)	Inhibits NFkB	Durable Tre	atment Regir	nen⁺
AXT107 (AsclepiX)	~	$\checkmark$		~	~	1-2		/
Eylea* (Regeneron)	$\checkmark$					7 ///	11	
Lucentis* (Genentech)	$\checkmark$					12	())))	()))
Vabysmo* (Roche)	$\checkmark$		$\checkmark$			6-8	//	
KSI-301 (Kodiak)	$\checkmark$					5	1	/


# AXT107 is Differentiated by its Long-Lasting Durability

**AXT107** potentially requires only 1-2 IVTs per year:

- significantly fewer IVTs than SoC and late-stage programs in development
- potential to improve treatment options for patients and meaningfully impact quality of life

Total # of Injections per Year<sup>+</sup>

Loading Doses and Maintenance Injections<sup>+</sup>



AXT107 (AsclepiX)
 Lucentis\* (Genentech)
 KSI-301 (Kodiak)

Eylea\* (Regeneron)Vabysmo\* (Roche)


\* Approved product + First year of treatment



# Preclinical Data of AXT107



### AXT107 Preclinical Data Demonstrates Multimodal Mechanism of Action




### AXT107 Inhibits Neovascularization and Vascular Leakage In Vitro


### Endothelial Cells in Culture<sup>1</sup>

Staining for VE-Cadherin and Actin on Endothelial Cells

Jagged and Irregular VE-Cadherin



Well formed endothelial cell junctions with co-localized Actin and VE-Cadherin <sup>2</sup>





10 µM AXT107

32 µM AXT107

100 µM AXT107


Co-localized Actin and VE-Cadherin at Cell-Cell Junction

1. A Mirando et al Collagen IV Derived Peptide Disrupts  $\alpha_5\beta_1$  Integrin Potentiates Ang2 Tie2


Signaling JCI Insight February 21, 2019


2. I Chrifi et al CMTM4 regulates angiogenesis by promoting cell surface recycling of VE-cadherin to endothelial adherens junctions Angiogenesis 2019

### AXT107 Suppresses Vascular Inflammation In Vitro




- Nucleus is stained in blue
- activates transcription of inflammatory proteins like VCAM-1 and ICAM-1
- AXT107 suppresses inflammation as NFkB remains in cytoplasm and levels of inflammatory proteins like VCAM-1 and ICAM-1 are reduced






SOURCE: Mirando, A.C.; Lima e Silva, R.; Chu, Z.; Campochiaro, P.A.; Pandey, N.B.; Popel, A.S. Suppression of Ocular Vascular Inflammation through Peptide-Mediated Activation of Angiopoietin-Tie2 Signaling. Int. J. Mol. Sci. 2020, 21, 5142.

# AXT107 Compared Favorably to Eylea (aflibercept) in Animal Models



- AXT107 showed statistically significant ۰ inhibition of leakage up through 30 days
- Remaining leakage is reduced by 55% compared to Eylea



Single administration of AXT107 inhibited ۲ leakage up through 60 days, while Eylea is inactive by day 60



# Latest Phase 1/2a Clinical Data



# Phase 1/2a Study of AXT107 in nAMD

Open-label, doseescalating, 48-week study

Assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 100 mcg, 250 mcg, or 500 mcg of AXT107 Data in low dose cohort (n=3) - all subjects dosed at 100 mcg

#### **Baseline Characteristics:**

- Ages 76 84 years old, with clinical history of responding to anti-VEGF injections
- Number of anti-VEGF injections in 12 months prior to baseline: 1-4
- BCVA (letters): 21– 64 at baseline

#### Primary Objective: safety

**Secondary Objectives:** efficacy measured by retinal thickness (central subfield thickness: CST) and Best Corrected Visual Acuity (BCVA)

Open-label, doseescalating, 48-week study

Assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 100 mcg, 250 mcg, or 500 mcg of AXT107 Data in low dose (100 mcg) and mid dose (250 mcg) cohorts - 3 subjects in each cohort


#### **Baseline Characteristics:**

- Age range: 55 75 years old
- Number of anti-VEGF injections in 12 months prior to baseline: 4-12
- BCVA letters: 56– 65 at baseline

#### Primary Objective: safety

**Secondary Objectives:** efficacy measured by retinal thickness (central subfield thickness: CST) and Best Corrected Visual Acuity (BCVA)

### Multiple Value-Driving Clinical/Regulatory Milestones in the Next Six Months





Committed leadership team with extensive experience in clinical development in retinal diseases



**AXT107:** new chemical entity impacting multiple pathways currently in Phase 1/2a studies for nAMD and DME

- Inhibits VEGF family and neovascularization
- Activates TIE2 and reduces vascular permeability and leakage
- Suppresses NFkB-mediated vascular inflammation

Preclinical data compared favorably to Eylea (aflibercept)



A total of 9 subjects completing study (48 weeks)



Multiple value-driving clinical milestones in 2022

#### NON-CONFIDENTIAL

# AsclepiX Summary



Corporate Headquarters

301 W 29th Street, Suite 2004 Baltimore, Maryland 21211

info@asclepix.com







Vision Measured by Best Corrected Visual Acuity (BCVA)

### NCKZO<sup>20/200</sup>NCKZO RHSDK RHSDK DOVHR DOVHR CZRHS CZRHS ONHRC NHRC Ο DKSNV ZSOKN 20/40 CKDNR


**Example:** 

**15-letter gain** (3 lines on ETDRS chart)

**20/40 BCVA Snellen equivalent** (minimum driving equivalent)

### In macular diseases, retinal thickness is correlated with greater vision loss

Widely used diagnostic imaging for retinal disease enabling visualization of the vitreous, retinal layers, retinal pigment epithelium, and choroidal layers



ASCLEPIX 25